Combination therapy with mutant IDH inhibitors

A combination therapy targeting IDH mutations and Flt3 kinase with specific inhibitors and agents effectively reduces 2-HG levels and suppresses AML progression, addressing resistance and promoting differentiation in mutant IDH-related cancers.

JP7596399B2Active Publication Date: 2024-12-09ELI LILLY & CO
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022557831
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-07-20
Filing Date
2021-03-22
Publication Date
2024-12-09
Estimated Expiration
2041-03-22

AI Technical Summary

Technical Problem

Current treatments for mutant IDH-related cancers, such as acute myeloid leukemia (AML), are limited by resistance mutations and high concentrations of 2-hydroxyglutarate, which inhibit cell differentiation and promote leukemogenesis, and there is a need for alternative therapies that target IDH mutations and Flt3 kinase mutations.

Method used

A combination therapy using mutant IDH inhibitors, antimetabolites, hypomethylating agents, and mutant Flt3 inhibitors, administered in various sequences or formulations, to target IDH1 and IDH2 mutations, including specific compounds like Compound A, cytarabine, azacytidine, midostaurin, and venetoclax, to inhibit 2-HG production and enhance cell differentiation.

Benefits of technology

The combination therapy effectively reduces 2-HG levels, enhances cell differentiation, and suppresses AML progression in both bone marrow and peripheral blood, demonstrating improved treatment outcomes compared to individual therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596399000001
    Figure 0007596399000001
  • Figure 0007596399000002
    Figure 0007596399000002
  • Figure 0007596399000003
    Figure 0007596399000003
Patent Text Reader

Abstract

The present invention relates to combination therapy with (a) a mutant IDH inhibitor and (b) one or more of antimetabolite agents, hypomethylating agents, and mutant Flt3 (Flt3) inhibitors for the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to combination therapy with a mutant isocitrate dehydrogenase (IDH) inhibitor and one or more of antimetabolites, hypomethylating agents, and mutant FMS-like tyrosine kinase 3 (Flt3) inhibitors for the treatment of cancer. [Background technology]

[0002] IDH1 and IDH2 catalyze the conversion of isocitrate to α-ketoglutarate, which is converted to nicotinamide adenine dinucleotide phosphate (NADP + ) to NADPH (Megias-Vericat J, et al., Blood Lymph. Cancer: Targets and Therapy 2019; 9: 19~32).

[0003] De novo mutations in IDH1, for example at IDH1 amino acid residue R132, contribute to tumorigenesis in several types of cancer, including solid tumor cancers and hematological malignancies (Badur MG, et al., Cell Reports 2018; 25: 1680). IDH1 mutations can result in high concentrations of 2-hydroxyglutarate (2-HG) and inhibit cell differentiation, and inhibitors of mutant IDH1 can decrease 2-HG concentrations and promote cell differentiation (Molenaar RJ, et al., Oncogene 2018; 37: 1949~1960). Mutations also occur in IDH2, e.g., at amino acid residues R172, R140 and R172 (Yang H, et al., Clin. Cancer. Res. 2012; 18: 5562-5571; Mondesir J, et al., J. Blood Med. 2016; 7: 171-180).

[0004] For example, acute myeloid leukemia (AML) is characterized by a multiclonal genomic architecture that contains multiple types of mutated genes and pre-leukemic and leukemic clones that dynamically evolve over time under therapeutic selection pressure (Bloomfield CD, et al., Blood Revs. 2018; 32: 416-425).

[0005] Induction chemotherapy with cytarabine and anthracycline ("7+3") has been the standard of care for newly diagnosed AML subjects for over 40 years.

[0006] Recently, five additional drugs have been approved by the U.S. Food and Drug Administration for the treatment of AML (midostaurin, enasidenib, CPX-351, gemtuzumab, and ozogamicin) (Megias-Vericat J, et al., Blood Lymph. Cancer: Targets and Therapy 2019; 9: 19-32).

[0007] Approximately 60% to 70% of adults with AML are expected to achieve complete remission (CR) after appropriate induction therapy, and more than 25% of adults with AML (approximately 45% of those who achieve CR) are expected to survive for more than 3 years and be cured.

[0008] However, IDH1 resistance mutations are found in 7-14% of AML subjects, and the associated high concentrations of 2-HG can lead to an epigenetic hypermethylation phenotype and impaired differentiation, which can lead to leukemogenesis (Megias-Vericat J, et al., Blood Lymph. Cancer: Targets and Therapy 2019; 9: 19-3). Furthermore, Flt3 kinase mutations are found in approximately one-third of AML subjects (Lee HJ, et al., Oncotarget 2018; 9: 924-936). Summary of the Invention [Problem to be solved by the invention]

[0009] Therefore, there remains a need for alternative therapies for mutant IDH-associated cancers.

[0010] Certain mutant IDH1 and IDH2 inhibitors are disclosed in WO 2018 / 111707 A1 and include a compound (WO 2018 / 111707 A1), defined herein as "Compound A", which is a covalent inhibitor of mutant IDH1 that modifies a single cysteine ​​(Cys269) located in the allosteric binding pocket, rapidly inactivating the enzyme and selectively inhibiting the production of 2-HG without affecting (α-KG) concentrations. [Means for solving the problem]

[0011] The present invention provides a method for administering a therapeutically effective amount of (a) Formula (I): [ka] [In the formula, R 1 is -CH2CH(CH3)2, -CH2CH3, -CH2CH2OCH3, or -CH2-cyclopropyl; R 2 is -CH3 or -CH2CH3; and X is N or CH. or a pharma- ceutically acceptable salt thereof; and (b) one or more of a second compound that is an antimetabolite, or a pharma- ceutically acceptable salt thereof; a hypomethylating agent, or a pharma- ceutically acceptable salt thereof; and a mutant Flt3 inhibitor, or a pharma- ceutically acceptable salt thereof. The present invention provides a method for treating cancer, comprising administering

[0012] In one embodiment, the IDH mutation is an IDH1 mutation or an IDH2 mutation. In another embodiment, the IDH mutation is an IDH1 mutation. In another embodiment, the IDH1 mutation is an IDH1 R132 mutation. In another embodiment, the IDH1 mutation is R132H. In another embodiment, the IDH1 mutation is R132C, R132G, R132L, or R132S. In another embodiment, the IDH1 R132 mutation is R132H. In another embodiment, the IDH1 mutation is R132C. In another embodiment, the IDH1 mutation is R132G. In another embodiment, the IDH1 mutation is R132L. In another embodiment, the IDH1 mutation is R132S.

[0013] In another embodiment, the IDH mutation is an IDH2 mutation. In another embodiment, the IDH2 mutation is an IDH2 R140 mutation or an IDH2 R172 mutation. In another embodiment, the IDH2 mutation is an R140 mutation. In another embodiment, the R140 mutation is R140Q, R140L, or R140W. In another embodiment, the IDH2 mutation is an R172 mutation. In another embodiment, the R172 mutation is R172K, R172M, R172G, R172S, or R172W.

[0014] In one embodiment of the method of the present invention, in the first compound of formula I, or a pharma- ceutically acceptable salt thereof, X is N. In another embodiment, in the first compound of formula I, or a pharma- ceutically acceptable salt thereof, X is N and R 1 is -CH2-cyclopropyl, R 2 In another embodiment, in the formula of the first compound, X is N and R 1 is -CH2-cyclopropyl, R 2 is -CH2CH3.

[0015] In another embodiment, the first compound is 7-[[(1S)-1-[4-[(1R)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one; 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one; or 1-Ethyl-7-[[(1S)-1-[4-[1-(4-prop-2-enoylpiperazin-1-yl)propyl]phenyl]ethyl]amino]-4H-pyrimido[4,5-d][1,3]oxazin-2-one; or a pharma- ceutically acceptable salt thereof.

[0016] In another embodiment the first compound is 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one.

[0017] In another embodiment, the first compound is [ka] or a pharma- ceutically acceptable salt thereof.

[0018] In another embodiment, the first compound is Compound A.

[0019] In another embodiment, the subject is identified to have an IDH1 mutation, e.g., an R132 IDH1 mutation. In another embodiment, the subject is identified to have an IDH2 mutation, e.g., an IDH2 R172, R140, or R172 mutation. In another embodiment, the subject is identified to have an IDH mutation in a tissue.

[0020] In another embodiment, the cancer is a hematological malignancy and the subject is identified as having an IDH mutation in blood, bone marrow, lymph nodes, or lymph, hi another embodiment, the subject is identified as having an IDH mutation in blood cells, bone marrow cells, lymph node cells, or lymph cells.

[0021] In another embodiment, the cancer is a solid tumor cancer and the subject is identified as having an IDH1 mutation in the solid tumor tissue. In another embodiment, the subject is identified as having an IDH mutation in the solid tumor tissue cells.

[0022] In another embodiment, prior to administration of a mutant Flt3 inhibitor, the human subject is identified as having a Flt3 mutation. In another embodiment, the Flt3 mutation is a Flt3 internal tandem duplication (Flt3-ITD) mutation. In another embodiment, the Flt3 mutation is a Flt3 tyrosine kinase domain (Flt3-TKD) mutation. In another embodiment, the Flt3 mutation is a Flt3 D835 mutation.

[0023] In another embodiment, the first compound, or a pharma- ceutically acceptable salt thereof, is administered prior to the second compound, or a pharma- ceutically acceptable salt thereof.

[0024] In another embodiment, the first compound, or a pharma- ceutically acceptable salt thereof, is administered after the second compound, or a pharma- ceutically acceptable salt thereof.

[0025] In another embodiment, the first compound, or a pharma- ceutically acceptable salt thereof, is formulated with the second compound, or a pharma- ceutically acceptable salt thereof.

[0026] In another embodiment of the method of the present invention, the cancer is a solid tumor cancer. In another embodiment, the solid tumor cancer is cholangiocarcinoma, head and neck cancer, chondrosarcoma, hepatocellular carcinoma, melanoma, pancreatic cancer, astrocytoma, oligodendroglioma, glioma, glioblastoma, bladder cancer, colorectal cancer, lung cancer, or paranasal sinus undifferentiated carcinoma. In another embodiment, the lung cancer is non-small cell lung cancer. In another embodiment, the lung cancer is non-small cell lung cancer, and α-KR G12C inhibitor and / or EGFR inhibitor are also administered. In another embodiment, the solid tumor is cholangiocarcinoma. In another embodiment, radiation therapy is also administered to the subject.

[0027] In another embodiment, the cancer is a hematological malignancy. In another embodiment, the hematological malignancy is AML, myelodysplastic syndrome, myeloproliferative neoplasm, angioimmunoblastic T-cell lymphoma, T-cell acute lymphoblastic leukemia, chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, primary myelofibrosis, or chronic myelogenous leukemia. In another embodiment, the hematological malignancy is AML.

[0028] In another embodiment of the method of the present invention, the second compound is an antimetabolite, or a pharmaceutically acceptable salt thereof. In another embodiment of the method of the present invention, the antimetabolite is cytarabine, 5-fluorouracil (5-FU), 6-mercaptourine (6-MP), capecitabine, floxuridine, fludarabine, gemcitabine, hydroxycarboxamide, methotrexate, pemetrexed, or phototrexate, or a pharmaceutically acceptable salt of any one of them. In another embodiment, the antimetabolite is cytarabine, or a pharmaceutically acceptable salt thereof. In another embodiment, the antimetabolite is cytarabine. In another embodiment, the first compound is compound A and the second compound is cytarabine. In another embodiment, the cancer is AML, the first compound is compound A, and the second compound is cytarabine. In another embodiment, the cancer is cholangiocarcinoma, the first compound is compound A, and the second compound is cytarabine.

[0029] In another embodiment of the method of the present invention, the second compound is a hypomethylating agent, or a pharma- ceutically acceptable salt thereof. In another embodiment of the method of the present invention, the hypomethylating agent is azacitidine (5-azacitidine), 5-aza-2'-deoxycitidine (decitabine), guadecitabine (SGI-110), 5-fluoro-2'-deoxycitidine, zebularine, CP-4200, RG108, nanaomycin A, or a pharma- ceutically acceptable salt of any one of them. In another embodiment, the hypomethylating agent is azacitidine, or a pharma- ceutically acceptable salt thereof. In another embodiment, the hypomethylating agent is azacitidine. In another embodiment, the first compound is compound A and the second compound is azacitidine. In another embodiment, the cancer is AML, the first compound is Compound A, and the second compound is Azacitidine. In another embodiment, the cancer is cholangiocarcinoma, the first compound is Compound A, and the second compound is Azacitidine.

[0030] In another embodiment, the first compound of formula I, or a pharma- ceutically acceptable salt thereof, is administered with a hypomethylating agent, or a pharma- ceutically acceptable salt thereof, and a Bcl-2 inhibitor, or a pharma- ceutically acceptable salt thereof. In another embodiment, the first compound of formula I, or a pharma- ceutically acceptable salt thereof, is administered with a hypomethylating agent and a Bcl-2 inhibitor. In another embodiment, the Bcl-2 inhibitor is venetoclax, obatoclax, navitoclax, or a pharma- ceutically acceptable salt of any one of them. In another embodiment, the Bcl-2 inhibitor is venetoclax, or a pharma- ceutically acceptable salt thereof. In another embodiment, the Bcl-2 inhibitor is venetoclax. In another embodiment, compound A is administered with a hypomethylating agent and a Bcl-2 inhibitor. In another embodiment, compound A is administered with azacitidine and venetoclax. In another embodiment, the cancer is AML and compound A is administered with azacitidine and venetoclax. In another embodiment, the cancer is cholangiocarcinoma and Compound A is administered with azacitidine and venetoclax.

[0031] In another embodiment of the method of the present invention, the second compound is a mutant Flt3 inhibitor, or a pharmaceutically acceptable salt thereof. In another embodiment of the method of the present invention, the mutant Flt3 inhibitor is midostaurin, gilteritinib, quizartinib (AC220), sorafenib, sunitinib, lestaurtinib, or crenolanib, or a pharmaceutically acceptable salt of any one of them. In another embodiment, the mutant Flt3 inhibitor is midostaurin, or a pharmaceutically acceptable salt thereof. In another embodiment, the mutant Flt3 inhibitor is midostaurin. In another embodiment, the first compound is compound A, and the second compound is midostaurin. In another embodiment, the cancer is AML, the first compound is compound A, and the second compound is midostaurin. In another embodiment, the cancer is cholangiocarcinoma, the first compound is compound A, and the second compound is midostaurin.

[0032] In another embodiment of the method of the present invention, Compound A is administered in combination with an antimetabolite and a hypomethylating agent.

[0033] In another embodiment of the method of the present invention, Compound A is administered in combination with an antimetabolite and a mutant Flt3 inhibitor.

[0034] In another embodiment of the method of the present invention, Compound A is administered in combination with a hypomethylating agent and a mutant Flt3 inhibitor.

[0035] In another embodiment of the method of the present invention, Compound A is administered in combination with an antimetabolite, a hypomethylating agent and a mutant Flt3 inhibitor.

[0036] The present invention relates to a compound represented by the following formula (I): [ka] [In the formula, R 1is -CH2CH(CH3)2, -CH2CH3, -CH2CH2OCH3, or -CH2-cyclopropyl; R 2 is -CH3 or -CH2CH3; and X is N or CH. or a pharmaceutically acceptable salt thereof, for use in treatment of cancer in a human subject having an IDH mutation in combination with one or more of an antimetabolite, or a pharmaceutically acceptable salt thereof; a hypomethylating agent, or a pharmaceutically acceptable salt thereof; or a mutant Flt3 inhibitor, or a pharmaceutically acceptable salt thereof.

[0037] In one embodiment, the subject is identified as having an IDH mutation, e.g., an IDH1 or ID2 mutation, in blood, bone marrow, lymph nodes, lymph, blood cells, bone marrow cells, lymph node cells, or lymph cells.

[0038] In another embodiment, the compound of Formula I is used in combination with a hypomethylating agent (e.g., azacytidine), or a pharmaceutically acceptable salt thereof, and a Bcl-2 inhibitor, or a pharmaceutically acceptable salt thereof, in the treatment of cancer in a human subject identified as having an IDH1 R132 mutation.

[0039] In one embodiment, the IDH mutation is an IDH1 mutation or an IDH2 mutation. In another embodiment, the IDH mutation is an IDH1 mutation. In another embodiment, the IDH1 mutation is an IDH1 R132 mutation. In another embodiment, the IDH1 mutation is R132H, R132C, R132G, R132L, or R132S. In another embodiment, the IDH1 R132 mutation is R132H. In another embodiment, the IDH1 mutation is R132C. In another embodiment, the IDH1 mutation is R132G. In another embodiment, the IDH1 mutation is R132L. In another embodiment, the IDH1 mutation is R132S.

[0040] In another embodiment, the IDH mutation is an IDH2 mutation. In another embodiment, the IDH2 mutation is an IDH2 R140 mutation or an IDH2 R172 mutation. In another embodiment, the IDH2 mutation is an R140 mutation. In another embodiment, the R140 mutation is R140Q, R140L, or R140W. In another embodiment, the IDH2 mutation is an R172 mutation. In another embodiment, the R172 mutation is R172K, R172M, R172G, R172S, or R172W.

[0041] In one embodiment, the subject is identified as having an IDH mutation, eg, an IDH1 or IDH2 mutation.

[0042] For compounds for use of formula I, preferred are compounds in which X is N, or a pharma- ceutically acceptable salt thereof; R 1 is -CH2-cyclopropyl, or a pharma- ceutically acceptable salt thereof; 2 is -CH2CH3, or a pharma- ceutically acceptable salt thereof; 1 is -CH2-cyclopropyl, or a pharma- ceutically acceptable salt thereof; 1is -CH2-cyclopropyl, and R 2 is -CH2CH3, or a pharma- ceutically acceptable salt thereof; 1 is -CH2-cyclopropyl, and R 2 More preferred are compounds in which X is N and R is -CH2CH3, or a pharma- ceutically acceptable salt thereof. 1 is -CH2-cyclopropyl, and R 2 The compound where is -CH2CH3 is most preferred.

[0043] Preferred compounds are 7-[[(1S)-1-[4-[(1R)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one; 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one; or 1-Ethyl-7-[[(1S)-1-[4-[1-(4-prop-2-enoylpiperazin-1-yl)propyl]phenyl]ethyl]amino]-4H-pyrimido[4,5-d][1,3]oxazin-2-one; or a pharma- ceutically acceptable salt thereof.

[0044] In another embodiment, the first compound is [ka] (Compound A), or a pharma- ceutically acceptable salt thereof.

[0045] In another embodiment, the first compound is Compound A.

[0046] A novel method of using a compound of formula I in combination with one or more of antimetabolites, hypomethylating agents, or mutant Flt3 inhibitors to treat cancer is presented herein.Thus, some aspects of the present invention provide a compound of formula I for use in combination with one or more of antimetabolites, hypomethylating agents, or mutant Flt3 inhibitors simultaneously, separately, or sequentially in the treatment of cancer in a subject identified to have an IDH mutation, for example, an IDH1 or IDH2 mutation.Furthermore, some aspects of the present invention provide a compound of formula I for use in combination with one or more of antimetabolites, hypomethylating agents, or mutant Flt3 inhibitors simultaneously, separately, or sequentially in the treatment of solid tumor cancer.Furthermore, some aspects of the present invention provide a compound of formula I for use in combination with one or more of antimetabolites, hypomethylating agents, or mutant Flt3 inhibitors simultaneously, separately, or sequentially in the treatment of hematological malignancies. Another aspect of the invention provides a compound of Formula I for use in combination, simultaneously, separately or sequentially, with a hypomethylating agent and a Bcl-2 inhibitor in the treatment of cancer in a subject identified as having an IDH mutation, e.g., an IDH1 or IDH2 mutation.

[0047] In one embodiment, the IDH mutation is an IDH1 mutation or an IDH2 mutation. In another embodiment, the IDH mutation is an IDH1 mutation. In another embodiment, the IDH1 mutation is an IDH1 R132 mutation. In another embodiment, the IDH1 mutation is R132H, R132C, R132G, R132L, or R132S. In another embodiment, the IDH1 R132 mutation is R132H. In another embodiment, the IDH1 mutation is R132C. In another embodiment, the IDH1 mutation is R132G. In another embodiment, the IDH1 mutation is R132L. In another embodiment, the IDH1 mutation is R132S.

[0048] In another embodiment, the IDH mutation is an IDH2 mutation. In another embodiment, the IDH2 mutation is an IDH2 R140 mutation or an IDH2 R172 mutation. In another embodiment, the IDH2 mutation is an R140 mutation. In another embodiment, the R140 mutation is R140Q, R140L, or R140W. In another embodiment, the IDH2 mutation is an R172 mutation. In another embodiment, the R172 mutation is R172K, R172M, R172G, R172S, or R172W.

[0049] The present invention also provides a pharmaceutical composition comprising a compound of Formula I for use in combination with one or more of an antimetabolite, or a pharma- ceutical acceptable salt thereof; a hypomethylating agent, or a pharma- ceutical acceptable salt thereof; or a mutant Flt3 inhibitor, or a pharma- ceutical acceptable salt thereof, in the treatment of cancer in a human subject identified as having an IDH mutation. In one embodiment, the IDH mutation is identified in blood cells, bone marrow cells, or blood and bone marrow cells.

[0050] The present invention also provides the use of a compound of formula I in the manufacture of a medicament for the treatment of cancer in a human subject having an IDH mutation, for example, an IDH1 or IDH2 mutation. In one embodiment, the subject has an IDH mutation identified in blood, bone marrow, lymph nodes, lymph, blood cells, bone marrow cells, lymph node cells, or lymph cells, and wherein the compound of formula I for use in the manufacture of a medicament is administered in combination with one or more of an antimetabolite, or a pharmaceutically acceptable salt thereof; a hypomethylating agent, or a pharmaceutically acceptable salt thereof; or a mutant Flt3 inhibitor; or a pharmaceutically acceptable salt thereof.

[0051] In one embodiment of the method or compound for use of the invention, the cancer is a frontline cancer. In another embodiment, the frontline cancer is a solid tumor cancer. In another embodiment, the frontline cancer is a hematological malignancy. In another embodiment, the frontline hematological malignancy is frontline AML.

[0052] In another embodiment of the method or compound for use of the present invention, the cancer is a recurrent cancer. In another embodiment, the recurrent cancer is a solid tumor cancer. In another embodiment, the recurrent cancer is a hematological malignancy. In another embodiment, the recurrent hematological malignancy is recurrent AML.

[0053] In another embodiment of the method or compound for use of the present invention, the cancer is a refractory cancer. In another embodiment, the refractory cancer is a solid tumor cancer. In another embodiment, the refractory cancer is a hematological malignancy. In another embodiment, the refractory hematological malignancy is refractory AML.

[0054] In another embodiment of the method or compound for use of the present invention, the cancer is an advanced cancer. In another embodiment, the advanced cancer is an advanced solid tumor cancer. In another embodiment, the advanced cancer is an advanced hematological malignancy. In another embodiment, the advanced hematological malignancy is advanced AML.

[0055] In another embodiment, the AML is acute promyelocytic leukemia.

[0056] Methods for assaying mutant IDH1 enzyme activity are known to those skilled in the art and are described, for example, in WO 2018 / 111707 A1.

[0057] As used above and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0058] The term "hematological tissue" refers to blood, bone marrow, spleen, lymph nodes, or lymph fluid.

[0059] The term "solid tumor tissue" refers to tissue that is not hematological tissue. Non-limiting examples of solid tissues are bile duct tissue, pancreatic tissue, head tissue, neck tissue, liver tissue, skin tissue, astrocytoma tissue, oligodendroglial tissue, glial tissue, brain tissue, bladder tissue, colorectal tissue, lung tissue, and sinonasal undifferentiated carcinoma tissue.

[0060] The term "solid tumor cancer" refers to cancer that originates in tissues other than the blood or bone marrow.

[0061] The term "hematological malignancy" relates to cancers that originate in the blood, bone marrow, lymph nodes or lymph fluid.

[0062] The term "frontline cancer" means that the human cancer subject has not received treatment for the cancer under treatment.

[0063] The term "refractory cancer" refers to a cancer that has been treated, but in which the human cancer subject does not respond to the treatment.

[0064] The term "recurrent cancer" means that a human cancer subject has responded to treatment for some period of time, but the cancer has recurred.

[0065] The term "advanced cancer" refers to cancer that has spread to lymph nodes or other tissues outside the origin of the cancer. For example, advanced AML is AML that has spread to tissues outside the blood or bone marrow.

[0066] The term "cancer subject" means a subject who has been diagnosed with cancer.

[0067] The term "solid tumor subject" refers to a subject who has been diagnosed with a solid tumor cancer. In one embodiment, the solid tumor cancer is cholangiocarcinoma.

[0068] The term "hematological malignancy subject" refers to a subject diagnosed with a hematological malignancy. In one embodiment, the hematological malignancy subject is an AML subject. The term "AML subject" refers to a subject diagnosed with AML. Methods for diagnosing AML are known to those skilled in the art and are described, for example, in Dohner H, et al., Blood 2017; 129: 424-447.

[0069] The terms "acute myeloid leukemia," "acute myelogenous leukemia," and "acute nonlymphocytic leukemia" are synonymous.

[0070] "Responsiveness to hematologic malignancy (e.g., AML) therapy" includes improved overall survival, partial response, long-term stable disease, or improved long-term survival as determined by <5% myeloblasts in the bone marrow, no blasts in the circulating blood, and hematologic recovery (peripheral blood absolute neutrophil count ≥1,000 cells / μL and platelet count ≥100,000 / μL, no need for red blood cell transfusions, and no extramedullary disease) (Bloomfield CD, et al., Blood Revs. 2018; 32: 416-425).

[0071] The term "IDH1 R132 mutation" is synonymous with "R132 IDH1 mutation" and refers to an IDH1 mutation at amino acid residue 132 in a subject's IDH1 gene, e.g., as determined in the subject's nucleic acid (e.g., DNA).

[0072] The term "Flt3 mutation" refers to a mutation in a subject's Flt3 gene.

[0073] The term "mutated IDH inhibitor" refers to a compound that inhibits the enzymatic activity of mutant IDH enzyme and / or the production of 2-HG by mutant IDH enzyme. Methods for assaying mutant IDH1 and IDH2 enzyme activity are known to those skilled in the art and are described, for example, in WO 2018 / 111707 A1. In the term "mutated IDH inhibitor", the word "mutation" refers to the IDH gene, not the inhibitor.

[0074] The term "mutant Flt3 inhibitor" refers to a compound that inhibits mutant Flt3 kinase activity. Methods for assaying mutant Flt3 activity are known to those skilled in the art, for example, as described in Lee HJ, et al., Oncotarget 2018; 9: 924-936. In the term "mutant Flt3 inhibitor", the word "mutant" refers to Flt3 protein, not to the inhibitory compound.

[0075] The term "identified as having an IDH mutation, e.g., an IDH1 or IDH2 mutation" means that nucleic acid (e.g., DNA) from tissues or cells of a human subject has been analyzed to determine whether the human subject has an IDH mutation. In one embodiment, the blood, bone marrow, lymph nodes, lymph, blood cells, bone marrow cells, lymph node cells, or lymph cells of the human subject have been analyzed for IDH mutations. In another embodiment, solid tissue of the human subject has been analyzed for IDH mutations.

[0076] The term "Bcl-2 inhibitor" refers to a compound that binds to Bcl-2 and causes one or more of the following: cytotoxicity in cancer cells, downregulation of Bcl-2 expression in cancer cells, mitochondrial dysfunction in cancer cells, and apoptosis in cancer cells. Methods for measuring the effect are known to those skilled in the art and are described, for example, in Wen M, et al., Front. Pharmacol. 2019; 10: 391.

[0077] In one embodiment of the method of the present invention, the party that identifies the human subject as having an IDH1 R132 mutation can be different from the party that administers the first and second compounds. In another embodiment, the party that identifies the human subject as having an IDH1 R132 mutation is different from the party that administers the first and second compounds. In another embodiment, the party that identifies the human subject as having an IDH1 R132 mutation is the same as the party that administers the first and second compounds.

[0078] The term "confirmed to have an Flt3 mutation" means that nucleic acid (e.g., DNA) from blood cells, bone marrow cells, or blood cells and bone marrow cells of a human subject has been analyzed to determine whether the human subject has one or more Flt3 mutations.

[0079] Analytical methods for confirmation of IDH1 and Flt3 mutations are known to those skilled in the art (Clark, O., et al., Clin. Cancer. Res. 2016; 22: 1837-42) and include, but are not limited to, karyotyping (Guller JL, et al., J. Mol. Diagn. 2010; 12: 3-16), fluorescent in situ hybridization (Yeung DT, et al., Pathology 2011; 43: 566-579), Sanger sequencing (Lutha, R et al., Haematologica 2014; 99: 465-473), metabolic profiling (Miyata S, et al., Scientific Reports 2019; 9: 9787), polymerase chain reaction (Ziai, JM and AJ Siddon, Am. J. Clin. Pathol 2015; 144: 539-554), and next-generation sequencing (e.g., whole transcriptome sequencing) (Lutha, R et al., Haematologica 2014; 99: 465-473; WangH-Y, et al., J. Exp. Clin. Cancer Res. 2016; 35: 86).

[0080] The terms "treatment," "treat," "treating," and the like, are intended to encompass slowing, halting, or reversing the progression of cancer. These terms also encompass alleviating, ameliorating, attenuating, eliminating, or reducing one or more symptoms of a disorder or disease, even if the cancer is not actually eliminated, and even if the progression of the cancer itself is not slowed, halted, or reversed.

[0081] "Therapeutically effective amount" means the amount of a compound, or a pharma- ceutically acceptable salt thereof, administered to a subject that induces the subject's biological or medical response or desired therapeutic effect in the subject.

[0082] Therapeutic effective amount can be easily determined by the attending clinician as a person skilled in the art by using known techniques and observing the results obtained under similar circumstances.When determining the effective amount of a subject, the attending clinician considers several factors, including but not limited to the size, age and general health of each individual subject; the specific disease or disorder involved; the extent or involvement or severity of disease or disorder; the response of each individual subject; the specific compound administered; the method of administration; the bioavailability characteristics of the formulation administered; the administration regimen selected; the use of concomitant drugs; and other relevant circumstances.

[0083] The term "in combination with" means that the compound of formula I is used or is for use in combination with any one or more of an antimetabolite, or a pharma- ceutically acceptable salt thereof; a hypomethylating agent, or a pharma- ceutically acceptable salt thereof, optionally a Bcl-2 inhibitor, or a pharma- ceutically acceptable salt thereof; or a mutant Flt3 inhibitor; or a pharma- ceutically acceptable salt thereof, simultaneously, separately or sequentially, in the treatment of cancer in a human subject with an IDH mutation.

[0084] The compounds administered in the methods of the present invention may be suitably formulated as pharmaceutical compositions administered by any route that makes the compounds bioavailable. In some embodiments, such compositions are formulated for oral administration. Such pharmaceutical compositions and methods for their preparation are well known in the art (see, for example, Remington: The Science and Practice of Pharmacy (DB Troy, Editor, 21 st Edition, Lippincott, Williams & Wilkins, 2006).

[0085] A "pharmaceutically acceptable carrier, diluent, or excipient" is a medium generally accepted in the art for delivering a bioactive agent to a mammal, for example a human.

[0086] Those skilled in the art will understand that the compound administered in the method of the present invention can form salt.The compound can react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts.Such pharmaceutically acceptable acid addition salts and their general preparation methods are well known in the art.See, for example, P.Stahl,et al.,HANDBOOK OF PHARMACEUTICAL SALTS:PROPERTIES,SELECTION AND USE,(VCHA / Wiley-VCH,2008).

[0087] "Pharmaceutically acceptable salts" or "a soluble salt" refers to the relatively non-toxic, inorganic and organic salts of the compounds of the present invention (SM Berge, et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, Vol 66, No. 1, January 1977). EXAMPLES

[0088] material and method Compounds and Formulations For in vivo experiments, prepare each test article at the appropriate concentration in vehicle. For in vivo experiments, formulate Compound A in Acacia vehicle (water, 10% Acacia, 0.05% Antifoam [Dow Corning 1510-US]) with 1.1 molar equivalents of HCl. Prepare Compound A freshly at the appropriate concentration in vehicle every 7 days and store at 4°C between doses. Formulate Midostaurin (Medchem Express, batch / lot number 23950) in 20% PEG400 in water and prepare fresh every week (store at 4°C between doses). Prepare Cytarabine fresh every week by diluting stock solution of Cytarabine in sterile saline (injection 20 mg / mL (Pfizer injectables)). Formulate Azacitidine (Sigma, lot number MKBR7212) in sterile water and prepare fresh each day just before dosing.

[0089] In vivo human AML PDx models Primary human AML cells are injected into female NOD SCID Gamma (NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl / SzJ [Jackson Labs#005557]) mice (6 to 7 weeks old) via the tail vein to establish AML models. Two models are used in this experiment: (1) IDH1(R132H),NRas(Q61H) primary human AML and (2) IDH1(R132H),Flt3-ITD primary human AML. If necessary, splenocytes from tumor-bearing mice are used to grow and expand the models as described. Each test article is prepared with vehicle at the appropriate concentration as described above, and the drug to be tested in this experiment is administered to the animals at a dose of 10 μL / gram of body weight. Compound A-treated mice (PO, QD) are treated with the indicated doses for the duration of the experiment. The combination drugs are administered as follows: midostaurin 50mg / kg PO,QD (for 53 days, starting 7 days after the start of Compound A administration), cytarabine 2mg / kg IP [(QDx5, rest 2)x2] rest 14d and repeat (2 cycles, starting at the start of Compound A administration), azacytidine 1mg / kg IP [(QDx5, rest 2)x2] rest 14d and repeat (2 cycles, starting at the start of Compound A administration). Treated mice are evaluated in comparison with vehicle-treated control mice and naive control mice (non-tumor bearing). Body weights are recorded twice weekly. Whole blood samples (<100μL) are collected by submandibular bleeding into K-EDTA blood collection tubes once every 2 weeks during the experimental period and analyzed by FACS to observe the differentiation status and leukemic tumor burden in the experimental mice (plasma is collected periodically for 2-HG analysis during the experimental period). For plasma collection, for each subject, 50 to 70 μL of whole blood is aliquoted into 1.5 mL microtubes and centrifuged at 300 x g for 8 min (4°C). 10 μL of plasma is collected, transferred to a new 1.5 mL microtube, and frozen at -80°C for 2-HG LCMS analysis. Inhibition of 2-HG production is observed by evaluation of plasma 2-HG using plasma from vehicle-treated mice as controls, and naive mice.For flow cytometry, collect 50-70 μL of whole blood, add 60 μL staining / washing buffer (5% heat-inactivated (HI)-FBS (v / v) (Invitrogen 10082) in DPBS (HyClone SH30028)) per tube, pipette up and down 3 to 4 times, transfer 100 μL of blood suspension to a 5 mL polypropylene tube, stain, and analyze as described below.

[0090] AML PDx model expansion Mice engrafted with human IDH1(R132H) AML cells are confirmed to have progressive disease progression by flow cytometry of whole blood samples in a patient-derived IDH1(R132H) leukemia model. Spleens are processed and splenocytes are isolated as described below. 200 μL of splenocyte preparation per subject is injected IV (intravenous, tail vein) into recipient NSG mice. (10e per mL) 6 ~25e 6 pcs, 2e per mouse 6 ~5e 6 Use 100% viable white blood cells to expand the model). Monitor progression by flow cytometry analysis once every 4 weeks until AML is confirmed in peripheral blood (>0.2% human AML cells (%hCD33+hCD45+ out of total white blood cell count (WBCs)). Once engraftment is confirmed, observe mice once every 2 weeks until ready for experiments. Randomize mice and begin experiments when the average %human AML (out of total WBCs) reaches 2-8%.

[0091] Collect blood from under the jaw.

[0092] Processing and preparation of spleen / splenocytes After removal, the spleen is weighed and 3 / 4 of the spleen is placed in a standard sterile 15mL polypropylene conical tube containing PBS and placed on ice. The remaining 1 / 4 of the spleen is fixed in 10% NBF and sent for pathology examination. The spleen is placed in ice-cold sterile PBS in a 15mL collection tube. The spleen is removed from the collection tube and placed into a 100 micron 50mL conical tube cell strainer (BD Falcon #352360). The spleen is processed by gently rubbing the spleen tissue against the surface of the cell strainer in a circular motion with the tip of the plunger of a 5mL syringe. Between processing, the surface of the strainer is washed three times with 10mL room temperature sterile DPBS (HyClone SH30028). After no intact spleen tissue is visible, a final wash of the strainer is performed and the cell preparation is mixed up and down 15 times with a 10mL sterile serological pipette. Collect the cell pellet by centrifugation (300 x g) and wash three times with 30 mL sterile DPBS. Count the cells and resuspend them in DPBS at the desired implantation concentration.

[0093] Bone marrow harvest Bone marrow is harvested from the tibia and femur using a 27G to 25G needle attached to a 1 mL syringe containing 1 mL of PBS.

[0094] Flow cytometric analysis of human leukocytes Collect submandibular blood samples from in vivo experiments. Add fluorescently conjugated antibody stains according to the manufacturer's instructions (anti-human CD33-PE (clone WM53, BD catalog no. 555450), anti-human CD14-APC (clone MφP9, BD catalog no. 340436), anti-human CD15-V450 (clone HI98, BD catalog no. 561584), anti-human CD117-BV421 (clone YB5.B8, BD catalog no. 562434), anti-human CD11b-APCCy7 (clone ICRF44, BD catalog no. 557754), anti-human CD45-PECy7 (clone HI30, BD catalog no. 557748), and anti-human CD3-FITC (clone SK7, BD catalog no. 340542)). Incubate samples for 30 min at room temperature, protected from light. After incubation, 1.5mL 1X BD Lyse / Fix (BD Catalog No. 558049) is added to each sample at 37°C and incubated at room temperature for 12 minutes. The tubes are centrifuged at 300xg for 7 minutes. The BD Lyse / Fix solution is aspirated and the cell pellet is washed three times with stain / wash buffer (one wash step consists of: resuspending the pellet in 3mL stain / wash buffer, centrifuging at 300xg, and aspirating wash buffer). The fixed cells are then resuspended in 300 to 400μL stain / wash buffer. Samples are analyzed on a Becton Dickinson FACSVerse Flow Cytometer (Cat. No. 651155 Serial No. Z6511550447) using standard flow cytometry principles and techniques. Samples are analyzed on the same day that the samples were stained and fixed. Population gating and data analysis of population percentages are performed with the FACSuite software on the FACSVerse cytometer. Population percentages resulting from data analysis are plotted in Graphpad Prism or JMP 13. If an animal succumbs to disease or blood cannot be obtained for technical reasons on any given day, the data point is not counted for that day and therefore is not tested (ND).

[0095] LC-MS metabolite analysis in plasma of AML PDx modelsThe effect of IDH1 inhibition on the total concentration of 2-HG and α-KG is determined by liquid chromatography-mass spectrometry (LC-MS) of plasma. A calibration curve is prepared by spiking 2-HG and α-KG in water. The method utilized derivatization with O-benzylhydroxylamine prior to analysis by LC-MS. Ten microliters of each standard or sample is placed in a deep-well 96-well plate and combined with 100 μL of an internal standard solution containing 10 μM d5-3-hydroxyglutaric acid and 10 μM d6-α-KG. Plasma samples are then treated with 210 uL 4:3 methanol:chloroform, centrifuged, the supernatant removed, and dried. 100 uL of 1M O-benzylhydroxylamine in pyridine buffer (8.6% pyridine, pH 5) and 100 uL of 1M N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) in pyridine buffer are added to each sample. The derivatization reaction proceeds for 1 hour at room temperature. 300 μL of ethyl acetate is added to each sample using a Beckman Biomek FX liquid handler. The plate is sealed, vortexed for 5 minutes, and then spun in an Eppendorf 5810R centrifuge at 4000 rpm for 5 minutes. 220 μL of the top layer is transferred to a new 96-well plate. Samples are dried under heated nitrogen at 50°C and reconstituted with 100 uL of methanol / water (1:1). One microliter of the derivatized sample is injected into an LC-MS system consisting of a Shimadzu Prominence 20A HPLC system and a Thermo Quantum Ultra™ triple quadrupole mass spectrometer. Analytes are separated on a Water XBridge™ C18 column (2.1x50mm, 3.5 μm) at a flow rate of 0.6 mL / min. Mobile phase A is 0.1% formic acid in water and mobile phase B is methanol. The gradient profile was: 0 min, 5% B; 2 min, 100% B; 4.00 min, 100% B; 4.1 min, 5% B; 5.50 min, end. The mass spectrometer utilizes a HESI-II probe operated in positive ion selected reaction monitoring mode.A calibration curve is generated by plotting analyte concentration versus analyte / internal standard peak area ratio and performing a quadratic fit of the data with 1 / concentration weighting in Xcalibur™ software. Unknown analyte concentrations are back-calculated from the calibration curve.

[0096] statistical methods The Combination Analysis Method (Bliss Independence for IVEF experiments) can be used to analyze the results. A regular repeated measures model is fitted to log volume versus group and time. The Contrast statement is used to test for interaction effects at each time point with the two specific treatments used in combination. This is equivalent to the Bliss Independence method, which assumes that tumor volumes can theoretically reach 0, i.e., complete regression.

[0097] The expected additive response (EAR) for the combination is calculated on a tumor volume scale as response (EAR): EAR volume = V1 * V2 / V0, where V0, V1, and V2 are the estimated mean tumor volumes for vehicle control, treatment 1 alone, and treatment 2 alone, respectively. If the interaction test is significant, the combination effect is statistically declared to be more than additive or less than additive depending on whether the observed mean volume of the combination is less than or greater than the EAR volume, respectively. Otherwise, the statistical conclusion is additive.

[0098] If tumor growth arrest is the best expected response, the Bliss method can be applied directly to the % delta T / C values ​​to obtain the EAR percent response: EAR% delta T / C=Y1*Y2 / 100, where Y1 and Y2 are the percent delta T / C values ​​of the monotherapy.

[0099] 1. Combination of Compound A and Cytarabine In experiments performed essentially as described above, the results in Tables 1A-1D were obtained for the combination of Compound A and cytarabine.

[0100] [Table 1] Each column represents data from one animal.

[0101] At day 47, the % plasma AML cells for each treatment group are: A: vehicle (86%); B: compound A (39%); C: cytarabine (5.2%); and E: compound A + cytarabine (0.48%) (p<0.001).

[0102] [Table 2] Each column represents data from one animal.

[0103] At day 47, the %AML cell differentiation for each treatment group is: A: vehicle (10%); B: compound A (37%); C: cytarabine (8%); and E: compound A + cytarabine (71%) (p<0.001).

[0104] [Table 3] The % bone marrow AML clearance for each treatment group is: A: vehicle (94%); B: compound A (78%); C: cytarabine (63%); and compound A + cytarabine (14%) (p=0.0011).

[0105] [Table 4] The % plasma 2-HG for each treatment group is: A: vehicle (100%); B: compound A (3.4%); C: cytarabine (24%); and E: compound A + cytarabine (11%) (p=0.0004).

[0106] In conclusion, the combination of Compound A and cytarabine enhances the suppression of AML in both the bone marrow and the periphery.

[0107] 2. Combination of Compound A and Azacitidine In experiments performed essentially as described above, the results in Tables 2A-2D were obtained for the combination of Compound A and Azacitidine.

[0108] [Table 5] Each column represents data from one animal.

[0109] At day 43, the % plasma AML cells for each treatment group are: A: vehicle (71%); B: Compound A (52%); G: Azacitidine (22%); and H: Compound A + Azacitidine (9.7%) (p<0.023).

[0110] [Table 6] Each column represents data from one animal.

[0111] At day 43, the %AML cell differentiation for each treatment group is: A: vehicle (15%); B: compound A (37%); G: azacytidine (10%); and H: compound A + azacytidine (59%) (p<0.001).

[0112] [Table 7] The % bone marrow AML clearance for each treatment group is: A: vehicle (94%); B: Compound A (87%); G: Azacitidine (55%); and H: Compound A + Azacitidine (19%) (p=0.0032).

[0113] [Table 8] The % plasma 2-HG for each treatment group is: A: vehicle (100%); B: Compound A (-15%); G: Azacitidine (48%); and H: Compound A + Azacitidine (-9.6%) (p=0.1714).

[0114] In conclusion, the combination of Compound A and azacytidine enhances the suppression of AML in both the bone marrow and the periphery.

[0115] 3. Combination of Compound A and Midostaurin In experiments carried out essentially as described above, the results in Tables 3A-3D were obtained for the combination of Compound A and midostaurin.

[0116] [Table 9] [Table 10] Each column represents data from one animal.

[0117] At day 50, the % plasma AML cells for each treatment group were: A: vehicle (32%); B: 1 mg Compound A (37%); F: midostaurin (1.1%); and I: 1 mg Compound A + midostaurin (2.2%) (p=0.473).

[0118] At day 50, the % plasma AML cells for each treatment group were: A: vehicle (32%); C: 10 mg Compound A (2.8%); F: midostaurin (1.1%); and L: 10 mg Compound A + midostaurin (0.6%) (p=0.016).

[0119] At day 64, the % plasma AML cells for each treatment group were: A: vehicle (67%); B: 1 mg Compound A (51%); F: midostaurin (2.2%); and I: 1 mg Compound A + midostaurin (1.3%) (p=0.767).

[0120] At day 64, the % plasma AML cells for each treatment group were: A: vehicle (67%); C: 10 mg Compound A (1.1%); F: midostaurin (2.2%); and L: 10 mg Compound A + midostaurin (0.56%) (p<0.001).

[0121] At day 78, the % plasma AML cells for each treatment group were: A: vehicle (129%); B: 1 mg Compound A (65%); F: midostaurin (3.9%); and I: 1 mg Compound A + midostaurin (1.6%) (p=0.829).

[0122] At day 78, the % plasma AML cells for each treatment group were: A: vehicle (129%); C: 10 mg Compound A (0.66%); F: midostaurin (3.9%); and L: 10 mg Compound A + midostaurin (0.25%) (p<0.001).

[0123] [Table 11] Each column represents data from one animal.

[0124] At day 50, %AML cell differentiation for each treatment group is: A: vehicle (28%); B: 1 mg Compound A (43%); F: midostaurin (33%); and I: 1 mg Compound A + midostaurin (81%) (p<0.001).

[0125] At day 50, % AML cell differentiation for each treatment group is: A: vehicle (28%); C: 10 mg Compound A (79%); F: midostaurin (33%); and L: 10 mg Compound A + midostaurin (80%) (p 0.776).

[0126] [Table 12] The % bone marrow AML clearance for each treatment group is: A: vehicle (86%); B: 1 mg Compound A (90%); F: midostaurin (26%); and I: 1 mg Compound A + midostaurin (19%) (p=0.828).

[0127] The % bone marrow AML clearance for each treatment group is: A: vehicle (86%); C: 10 mg Compound A (2.3%); F: midostaurin (26%); and L: 1 mg Compound A + midostaurin (0.58%) (p=0.906).

[0128] [Table 13] The % plasma 2-HG for each treatment group is: A: vehicle (100%); B: 1 mg Compound A (38%); F: midostaurin (70%); and I: 1 mg Compound A + midostaurin (21%) (p=0.789).

[0129] The % plasma 2-HG for each treatment group is: A: vehicle (100%); C: 10 mg Compound A (9.2%); F: midostaurin (70%); and L: 10 mg Compound A + 10 mg midostaurin (6.8%) (p=0.373).

[0130] In conclusion, the combination of Compound A and midostaurin enhances the suppression of AML in both the bone marrow and the periphery.

Claims

1. The formula below: [Formula 1] or a pharma- ceutical composition comprising the compound of formula (I) or a pharma- ceutical acceptable salt thereof, in combination with one or more of: cytarabine, or a pharma- ceutical acceptable salt thereof; azacitidine, or a pharma- ceutical acceptable salt thereof; or midostaurin, or a pharma- ceutical acceptable salt thereof, for use in the treatment of acute myeloid leukemia in a human subject harboring an IDH mutation.

2. The composition of claim 1 , wherein the IDH mutation is an IDH1 mutation.

3. The composition of claim 2 , wherein the IDH1 mutation is an IDH1 R132 mutation.

4. The composition of claim 1 , wherein the IDH mutation is an IDH2 mutation.

5. 5. The composition of claim 4, wherein the IDH2 mutation is an IDH2 R140 or an IDH2 R172 mutation.

6. The compound or a pharma- ceutically acceptable salt thereof has the formula: [Case 2] The composition according to any one of claims 1 to 5, wherein the compound is 7. A composition according to any one of claims 1 to 6 for use in combination with at least cytarabine, or a pharma- ceutically acceptable salt thereof.

8. A composition according to any one of claims 1 to 6 for use in combination with at least azacitidine, or a pharma- ceutically acceptable salt thereof.

9. The composition of claim 8 further combined with a Bcl-2 inhibitor or a pharma- ceutically acceptable salt thereof.

10. The composition of claim 9, wherein the Bcl-2 inhibitor is venetoclax, or a pharma- ceutically acceptable salt thereof.

11. A composition described in any one of claims 1 to 6 for use in combination with at least midostaurin, or a pharma- ceutically acceptable salt thereof.

Citation Information

Patent Citations

  • IDH1 inhibitors for the treatment of hematological malignancies and solid tumors

    JP2019510746A

  • 7-Phenylethylamino-4H-pyrimido[4,5-D][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors

    JP2020502157A

  • Inhibiting mutant IDH-1

    WO2019222553A1